Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ImmuneOnco Biopharmaceuticals Co., Ltd.

http://immuneonco.com/

Latest From ImmuneOnco Biopharmaceuticals Co., Ltd.

Could CD47 Competitors Catch Up To Gilead After Magrolimab Hold?

Gilead isn’t giving details about the events behind the partial hold on magrolimab/Vidaza combination studies, but analysts suspect cytopenias are the culprit.

Clinical Trials ImmunoOncology

Oncology Developer Yahong Bags China’s First Biotech IPO Of 2022

Jiangsu Yahong and 11 Chinese biotechs raised a combined $1.1bn via public listings and VC/PE deals in the run-up to and first week of the new year.

China Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd.
UsernamePublicRestriction

Register